EVALUATION OF THE PIGMENT LIGHTENING EFFICACY AND TOLERANCE OF TEST PRODUCT IN WOMEN WITH HYPERPIGMENTATIO

AMRA Remedies0 个研究点目标入组 33 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Voluntary women with well defined hyperpigmented patch of not less than 2 cms on face (epidermal pigmentation).
•2.Between 18 and 45 years.
•3.Photo type IV and below.
•4.Presenting healthy skin on face.
•5.Accepting not to use products with the same end benefit or containing sunscreen during the entire study duration.
•6.Willing to avoid unusual sun exposure as far as possible for the entire study duration.
•7.For whom the Investigator considers that the compliance will be correct.
•8.Cooperating, informed of the need and duration of the examinations, and ready to comply with protocol procedures.
•9.Having signed a Consent Form and will be once informed orally and in writing of all information concerning the study procedures and study objectives.

•1.Pregnant women and lactating women or women planning pregnancy.
•2.Skin allergy antecedents or atopic subject.
•3.Hypersensitivity to any cosmetic product, raw material.
•4.Any clinically significant systemic or cutaneous disease, which may interfere with study treatments or procedures.
•5.Subjects on any medical treatment either systemic or topical which may interfere with the performance of the study treatment (presently or in the past 1 month).
•6.Subject in an exclusion period or already participating in another similar cosmetic or therapeutic trial as identified during screening on visit 1 (V1).

发起方

AMRA Remedies